Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation of 5'-deoxynucleoside monophosphate

A technology for deoxynucleoside mono- and deoxynucleotides, which is applied in the field of chemical synthesis of 5′-deoxynucleoside monophosphate, which can solve the problems of high production costs, complicated 5′-deoxynucleoside monophosphate methods, and high consumption. question

Active Publication Date: 2009-08-12
SHANGHAI ZHAOWEI TECH DEV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The currently used method for obtaining 5′-deoxynucleoside monophosphate is complicated, highly specific, high in production cost and large in consumption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0030] The preparation method of 5'-deoxynucleoside monophosphate provided by the present invention includes the steps of adding phosphorus and purification, specifically, through the following steps:

[0031] (1) 2'-deoxynucleosides, phosphorus oxychloride and trialkyl phosphate are mixed to obtain a solution containing 5'-deoxynucleotide crude products;

[0032] (2) hydrolyzing the solution containing the crude 5′-deoxynucleotide obtained in step (1) at pH ≥ 8.0 to obtain a hydrolyzate;

[0033] (3) mixing and extracting the organic solvent and the hydrolyzate of step (2), to obtain an organic phase and an aqueous phase; the organic solvent is a halogenated hydrocarbon;

[0034] (4) concentrating the aqueous phase to obtain a concentrate; and

[0035] (5) Crystallize the concentrated solution obtained in step (4) at 10 to 15° C. to obtain solid 5′-deoxynucleoside monophosphate.

[0036] Using 2'-deoxynucleoside as raw material, carry out phosphorylation reaction in trialky...

Embodiment 1

[0051] Preparation of 5′-deoxycytidine monophosphate

[0052] 1Kg of deoxycytidine and 30L of trimethyl phosphate were respectively fed into the reactor, stirred and cooled to -10°C, and then 3L of phosphorus oxychloride was added dropwise. After the dropwise addition, the reaction was continued for 4 hours, and the sample was analyzed by HPLC: the conversion rate of the target substance was 87.5%;

[0053] Add water for hydrolysis, control the temperature of the solution at about -10°C during the hydrolysis process, add NaOH to adjust the pH of the solution to 8.5;

[0054] Ethyl chloride was added for extraction, and the organic phase in the lower layer was separated after the extraction was completed and stilled. The final content of trimethyl phosphate in the organic phase was 10%. And the obtained aqueous phase was concentrated under reduced pressure to a solid content of 7%;

[0055] The concentrate was filtered until clear and adjusted to pH=3.8 with HCl. Control the...

Embodiment 2

[0058] Preparation of 5′-deoxyguanosine monophosphate

[0059] 1Kg of deoxyguanosine and 30L of trimethyl phosphate were respectively fed into the reaction kettle, and 2.8L of phosphorus oxychloride was added dropwise after stirring and cooling down to -15°C. After the dropwise addition, the reaction was continued for 3.5 hours, and the sample was analyzed by HPLC: the conversion rate of the target substance was 83.5%;

[0060] Add water for hydrolysis, control the temperature of the solution at about -8°C during the hydrolysis process, and add NaOH to adjust the pH of the solution to 8.7;

[0061] Ethyl chloride was added for extraction, and the organic phase in the lower layer was separated after the extraction was completed and stilled. The final content of trimethyl phosphate in the organic phase was 7.5%. The obtained aqueous phase was concentrated under reduced pressure to a solid content of 5%;

[0062] The concentrate was filtered until clear and adjusted to pH=3.2 w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
crystallization temperatureaaaaaaaaaa
Login to View More

Abstract

The invention discloses a preparing method of 5'-deoxyribonucleoside monophosphate, which comprises the following steps: (1) mixing 2'-deoxyribonucleoside, phosphorus oxychloride and trialkyphosphate to obtain a crude solution containing 5'-deoxynucleotide; (2) hydrolyzing the 5'-deoxynucleotide crude solution obtained from the step (1) in a solution with pH higher than or equal to 8.0 so as to an obtain hydrolysis liquid; (3) mixing an organic solvent, i.e. halogenated hydrocarbon, with the hydrolysis liquid obtained from the step (2), and extracting the mixture to obtain an organic phase and an aqueous phase; (4) condensing the aqueous phase to obtain a condensed liquid; and (5) placing the condensed liquid obtained from the step(4) at a temperature of 10-15 DEG C to obtain the solid 5'-deoxyribonucleoside monophosphate.

Description

technical field [0001] The invention relates to the field of chemical synthesis, in particular to a preparation process for chemically synthesizing 5'-deoxynucleoside monophosphate. Background technique [0002] Drugs based on deoxynucleosides and deoxynucleotides and their derivatives are a new class of biochemical drugs. In recent years, the research and application in the field of biomedicine have developed rapidly. Some studies have shown that such biopharmaceuticals will play an important role in human anti-inflammatory drugs in the future. important role in tumors. At present, research on anti-cancer, anti-virus, anti-fungal, anti-bacteria, treatment of myocardial infarction, as an interferon inducer and gene therapy is being deepened, and the curative effect is also obvious, and it has been widely used clinically (such as anti-cancer Drug 5-FdUR, Zalcitabine for the treatment of AIDS, etc.), with the deepening of research on such drugs, in addition to using natural d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H1/00C07H1/02C07H19/10C07H19/20
Inventor 单永磊
Owner SHANGHAI ZHAOWEI TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com